Sales growth for Trinity Biotech

Nasdaq-listed Trinity Biotech continued to generate solid sales growth, with sales in the third quarter up to $9

Nasdaq-listed Trinity Biotech continued to generate solid sales growth, with sales in the third quarter up to $9.5 million (€10.6 million) from $7.6 million.

Operating profits were up by the same margin to $4.7 million, from $3.8 million.

But expenses more than doubled, mainly as a result of increased investment in sales and marketing in the US and Germany.

  • —

    From maternity leave to remote working: Submit your work-related questions here

  • Listen to Inside Business podcast for a look at business and economics from an Irish perspective

  • Sign up to the Business Today newsletter for the latest new and commentary in your inbox